keyword
https://read.qxmd.com/read/37017751/expert-opinion-on-the-treatment-of-vulvovaginal-atrophy-with-ospemifene-based-on-new-evidence
#21
JOURNAL ARTICLE
S Palacios, R E Nappi, M J Cancelo, S Sánchez, T Simoncini
Vulvovaginal atrophy (VVA) is an underdiagnosed and undertreated chronic condition resulting in physiological and histological changes in the genitourinary tract of postmenopausal women. Treatment of moderate to severe VVA includes local estrogens, dehydroepiandrosterone (DHEA) and oral ospemifene, a third-generation selective estrogen receptor modulator (SERM). Due to venous thromboembolism (VTE) safety concerns classically associated with the SERM class, and as part of its original marketing authorization approval (MAA), the European Medicines Agency (EMA) requested the performance of a 5-year post-authorization safety study (PASS) to study the incidence rate of VTE among women receiving ospemifene...
August 2023: Climacteric: the Journal of the International Menopause Society
https://read.qxmd.com/read/37017707/satisfaction-and-medication-adherence-in-women-with-vulvovaginal-atrophy-the-creta
#22
JOURNAL ARTICLE
R Sánchez-Borrego, M V de Diego Pérez de Zabalza, M J Alfageme Gullón, M L Alija Castrillo, M Sánchez Prieto, S Palacios, A J González Calvo, J J Quijano Martín, M J Cancelo
OBJECTIVE: This study aimed to evaluate the self-reported satisfaction of Spanish postmenopausal women currently treated for vulvovaginal atrophy (VVA) symptoms. METHODS: The CRETA (CRoss sectional European sTudy on Adherence) is a multicenter cross-sectional study conducted in 29 public and private hospitals in Spain, which enrolled postmenopausal women receiving treatment with ospemifene, local hormone therapy (HT) or vaginal moisturizers for VVA. After the prior informed consent of the patients, sociodemographic and treatment perception data were collected using a structured questionnaire...
April 5, 2023: Climacteric: the Journal of the International Menopause Society
https://read.qxmd.com/read/36951262/new-developments-in-the-management-of-vulvovaginal-atrophy-a-comprehensive-overview
#23
REVIEW
Gilbert G G Donders, Francesca H W V Donders
INTRODUCTION: Proper recognition and individualized therapy of vulvovaginal atrophy (VVA) is paramount. AREAS COVERED: Assessment of VVA should be performed using several questionnaires in combination with wet mount microscopy to determine Vaginal Cell Maturation Index (VCMI) and infections. PubMed searches were carried out between 1 march 2022 and 15 October 2022.Low dose vaginal estriol seems safe, efficient, and could be used in patients with contraindications for steroid hormones such as women with a history of breast cancer, and should therefore be considered as first choice hormonal treatment, when non-hormonal treatments fail...
April 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36946290/treating-genitourinary-syndrome-of-menopause-in-breast-cancer-survivors-main-challenges-and-promising-strategies
#24
JOURNAL ARTICLE
C Castelo-Branco, E Mension, I Torras, I Cebrecos, S Anglès-Acedo
Many breast cancer survivors (BCS) suffer the consequences of antineoplastic treatments that induce a hypoestrogenic state, leading to chronic climacteric symptoms such as genitourinary syndrome of menopause (GSM), arousing significant alteration in their quality of life. Non-hormonal therapies (NHT) are first-line treatments, safe but with mild efficacy. When facing moderate-severe GSM, the options for BCS are limited: local estrogen therapy, considered the 'gold standard' but with concerns about safety; vaginal androgens and prasterone, which seem to trigger an activation of estrogen and androgen receptors of the vaginal epithelium layers, without activating estrogen receptors on other tissues, being potentially safe but still without strong evidence in favor of BCS; vaginal lasers, which appear to improve vascularization of vaginal mucosa by stimulating the remodeling of the underlying connective tissue, but with contradictory results of efficacy in recent randomized clinical trials; and ospemifene, an oral selective estrogen receptor modulator presenting mild vaginal estrogenic potency and anti-estrogenic effect at the endometrial and breast level, but still not recommended for use in BCS in recent North American Menopause Society guidelines...
August 2023: Climacteric: the Journal of the International Menopause Society
https://read.qxmd.com/read/36912363/effects-of-ospemifene-on-overactive-bladder-in-postmenopausal-women-with-vulvovaginal-atrophy
#25
JOURNAL ARTICLE
E Russo, G Misasi, M M Montt-Guevara, A Giannini, T Simoncini
OBJECTIVE: Overactive bladder (OAB) is a complex and multifactorial syndrome associated with urinary frequency, urgency and incontinence. The menopause-associated hormonal changes play a role in the development of this condition. Vaginal estrogens are effective in improving OAB in postmenopausal women (PMW) with vulvovaginal atrophy (VVA). Ospemifene is a selective estrogen receptor modulator licensed for the treatment of VVA. This study aimed to evaluate the effects of ospemifene on OAB symptoms in PMW with VVA...
June 2023: Climacteric: the Journal of the International Menopause Society
https://read.qxmd.com/read/36749328/management-of-menopausal-symptoms-a-review
#26
REVIEW
Carolyn J Crandall, Jaya M Mehta, JoAnn E Manson
IMPORTANCE: Menopause, due to loss of ovarian follicular activity without another pathological or physiological cause, typically occurs between the ages of 45 years and 56 years. During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symptoms) and more than 50% have genitourinary symptoms (genitourinary syndrome of menopause [GSM]). OBSERVATIONS: Vasomotor symptoms typically last more than 7 years and GSM is often chronic...
February 7, 2023: JAMA
https://read.qxmd.com/read/36727789/effect-of-ospemifene-on-vaginal-microbiome-in-postmenopausal-women-with-vulvovaginal-atrophy
#27
JOURNAL ARTICLE
Stefania Alvisi, Camilla Ceccarani, Claudio Foschi, Maurizio Baldassarre, Alessandra Lami, Marco Severgnini, Tania Camboni, Clarissa Consolandi, Renato Seracchioli, Maria Cristina Meriggiola
OBJECTIVES: This study aimed (i) to compare the vaginal microbiome profiles of women suffering from vulvovaginal atrophy with that of healthy postmenopausal women and to (ii) assess the effect of ospemifene and systemic hormone treatment on the composition of the vaginal microbiome. METHODS: Sixty-seven postmenopausal women attending the Gynecology Clinic of Azienda Ospedaliero-Universitaria of Bologna (Italy) were enrolled. Of them, 39 received a diagnosis of atrophy and 28 were considered healthy controls...
January 24, 2023: Menopause: the Journal of the North American Menopause Society
https://read.qxmd.com/read/36470539/drugs-for-the-treatment-of-postmenopausal-symptoms-hormonal-and-non-hormonal-therapy
#28
REVIEW
Meijun Pan, Jing Zhou, Xinyao Pan, Jing Wang, Qing Qi, Ling Wang
Postmenopausal symptoms are systemic symptoms associated with estrogen deficiency after menopause. At present, treatments for postmenopausal symptoms include hormonal therapy (HT) and non-HT. However, the optimal regimen for balancing the benefits and risks remains unclear. This article reviewed the characteristics, regimens, and side effects of drugs used in hormonal and non-HT. However, HT is still the most effective treatment with safety in early initiation since menopause onset. Nevertheless, it is essential to evaluate the risks of related chronic diseases and customize individualized treatments...
December 2, 2022: Life Sciences
https://read.qxmd.com/read/36446564/efficacy-of-hormonal-and-nonhormonal-approaches-to-vaginal-atrophy-and-sexual-dysfunctions-in-postmenopausal-women-a-systematic-review
#29
REVIEW
Ayane Cristine Alves Sarmento, Ana Paula Ferreira Costa, Juliana Lírio, José Eleutério, Pedro Vieira Baptista, Ana Katherine Gonçalves
OBJECTIVE:  To evaluate the efficacy of the hormonal and nonhormonal approaches to symptoms of sexual dysfunction and vaginal atrophy in postmenopausal women. DATA SOURCES:  We conducted a search on the PubMed, Embase, Scopus, Web of Science, SciELO, the Cochrane Central Register of Controlled Trials (CENTRAL), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases, as well as on clinical trial databases. We analyzed studies published between 1996 and May 30, 2020...
October 2022: Revista Brasileira de Ginecologia e Obstetrícia
https://read.qxmd.com/read/36444726/current-challenges-in-the-pharmacological-management-of-genitourinary-syndrome-of-menopause
#30
REVIEW
Stefano Salvatore, Vittoria Benini, Alessandro Ferdinando Ruffolo, Rebecca S Degliuomini, Anna Redaelli, Arianna Casiraghi, Massimo Candiani
INTRODUCTION: Genitourinary syndrome of menopause is caused by climacteric estrogens drop and leads to bothersome and progressive genital and urinary symptoms. Considering the high frequency in the population and the impact on quality of life, it is crucial to find a safe and effective treatment. Pharmacological therapies aim to modulate the hormonal system and reverse tissue changes due to hypoestrogenism and consequently the symptoms. AREAS COVERED: We analyzed the scientific evidence concerning the main pharmacological treatments, which include systemic and topical estrogens, prasterone and ospemifene...
January 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36420373/risk-of-venous-thromboembolism-among-women-receiving-ospemifene-a-comparative-observational-study
#31
JOURNAL ARTICLE
Beth L Nordstrom, Bin Cai, Fabio De Gregorio, Lu Ban, Kathy H Fraeman, Yuki Yoshida, Trevor Gibbs
INTRODUCTION: The primary aim of this study was to compare the incidence of venous thromboembolism (VTE) among women initiating ospemifene vs other selective estrogen receptor modulator (SERM) therapies for estrogen-deficiency conditions or breast cancer prevention, and vs women with untreated vulvar and vaginal atrophy (VVA). The secondary objective examined numerous additional safety outcomes. METHODS: This was a retrospective cohort study using the IBM Watson MarketScan claims database...
2022: Therapeutic Advances in Drug Safety
https://read.qxmd.com/read/36362542/effect-of-ospemifene-on-densitometric-and-plasma-bone-metabolism-biomarkers-in-postmenopausal-women-reporting-vulvar-and-vaginal-atrophy-vva
#32
JOURNAL ARTICLE
Silvia Maffei, Letizia Guiducci
Menopausal hormone deficiency can exert multiple effects on various organs. Vulvovaginal atrophy (VVA) is among the most widespread and disabling post-menopausal disorder. Hormonal changes can also result in a markedly increased rate of bone mineral density (BMD) loss. Ospemifene (OSP) is an SERM indicated to treat vulvar and vaginal atrophy (VVA) in postmenopausal women. This study evaluates the long-term effects of ospemifene therapy on bone metabolism and bone mineral parameters in postmenopausal women reporting VVA/GSM...
October 26, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/35797481/the-2022-hormone-therapy-position-statement-of-the-north-american-menopause-society
#33
JOURNAL ARTICLE
(no author information available yet)
"The 2022 Hormone Therapy Position Statement of The North American Menopause Society" (NAMS) updates "The 2017 Hormone Therapy Position Statement of The North American Menopause Society" and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2017 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence...
July 1, 2022: Menopause: the Journal of the North American Menopause Society
https://read.qxmd.com/read/35744033/new-innovations-for-the-treatment-of-vulvovaginal-atrophy-an-up-to-date-review
#34
REVIEW
Vittoria Benini, Alessandro Ferdinando Ruffolo, Arianna Casiraghi, Rebecca S Degliuomini, Matteo Frigerio, Andrea Braga, Maurizio Serati, Marco Torella, Massimo Candiani, Stefano Salvatore
Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus and lower urinary tract. This condition is related to hypoestrogenism consequent to menopause onset but is also due to the hormonal decrease after adjuvant therapy for patients affected by breast cancer. Considering the high prevalence of VVA and the expected growth of this condition due to the increase in the average age of the female population, it is easy to understand its significant social impact. VVA causes uncomfortable disorders, such as vaginal dryness, itching, burning, and dyspareunia, and requires constant treatment, on cessation of which symptoms tend to reappear...
June 6, 2022: Medicina
https://read.qxmd.com/read/35670533/long-term-use-of-ospemifene-in-clinical-practice-for-vulvo-vaginal-atrophy-end-results-at-12-months-of-follow-up
#35
JOURNAL ARTICLE
Carmen Pingarrón Santofímia, Pilar Lafuente González, María Del Carmen Guitiérrez Vélez, Virginia Calvente Aguilar, Silvia Poyo Torcal, Pablo Terol Sánchez, Santiago Palacios
OBJECTIVE: To assess the improvement in vulvovaginal atrophy (VVA) of postmenopausal women treated with oral ospemifene 60 mg/day under conditions of routine clinical practice after 12 months of follow-up. METHODS: The AYSEX study is a Spanish observational, prospective, and unicentric study in which five gynecologists recruited postmenopausal women with VVA in routine clinical practice treated with oral ospemifene 60 mg/day as an appropriate therapeutic option...
July 2022: Gynecological Endocrinology
https://read.qxmd.com/read/35630054/management-of-hypertension-with-female-sexual-dysfunction
#36
REVIEW
Qing Zhong, Yuri Anderson
Female sexual dysfunction (FSD) in hypertension has been less studied than male sexual dysfunction, and antihypertensive agents' impact on female sexual function is not defined. In this review, randomized double-blind clinical trials and cross-sectional studies related to female sexual function in hypertension were analyzed from 1991 to 2021. FSD appeared to be higher in hypertensive women than in normotensive women. Beta-blockers are the only antihypertensive agents with relatively strong evidence of damaging the female sexual function...
May 5, 2022: Medicina
https://read.qxmd.com/read/35430926/pharmacotherapy-for-female-sexual-dysfunctions-fsds-what-is-on-the-market-and-where-is-this-field-heading
#37
JOURNAL ARTICLE
Rossella E Nappi, Lara Tiranini, Laura Cucinella, Ellis Martini, David Bosoni, Alessandra Righi, Chiara Cassani, Barbara Gardella
INTRODUCTION: Female sexual dysfunctions (FSDs) are common in women of any age and have a huge impact on quality of life and relationships. They have a multifaceted etiology limiting the development of pharmacotherapies with a high rate of effectiveness. Safety issues are also a concern. AREAS COVERED: The authors report the most recent advances in pharmacotherapy for premenopausal and postmenopausal women with a main focus on hypoactive sexual desire disorders (HSDD) and associated sexual symptoms...
January 2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/35420405/female-pelvic-conditions-genitourinary-syndrome-of-menopause
#38
JOURNAL ARTICLE
Patricia H Brady, Geneen T Gin, Elizabeth Rosenblum, Lesley D Wilkinson
Genitourinary syndrome of menopause (GSM) is a term that describes the genital, urinary, and sexual changes that occur in women because of a lack of estrogen. This most commonly is because of menopause, but can be because of a hypoestrogenic state caused by hyperprolactinemia, oophorectomy, premature ovarian failure, chemotherapy, or radiation. GSM describes a group of signs and symptoms that affect quality of life and progress over time, including vaginal dryness, dyspareunia, dysuria, urinary urgency, and frequent urinary tract infections...
April 2022: FP Essentials
https://read.qxmd.com/read/35337615/vaginal-metabolites-in-postmenopausal-women-with-or-without-vulvo-vaginal-atrophy-at-baseline-and-after-ospemifeme-and-systemic-hormone-treatment
#39
JOURNAL ARTICLE
Claudio Foschi, Stefania Alvisi, Maurizio Baldassarre, Luca Laghi, Giulia Gava, Ilaria Mancini, Paolo Casadio, Renato Seracchioli, Maria Cristina Meriggiola
OBJECTIVES: Vulvo-vaginal atrophy (VVA) is a highly prevalent chronic condition affecting the lives of postmenopausal women. Ospemifene and systemic hormone therapy (HT) improve vaginal health. This study aims to characterize the vaginal metabolic profile of women with VVA at baseline and after ospemifene and systemic HT. STUDY DESIGN: Sixty postmenopausal women, 32 of whom were affected by VVA, were consecutively enrolled.  The vaginal metabolic profile of women with and without VVA at baseline and after three months of ospemifene or HT treatment was assessed...
May 2022: Maturitas
https://read.qxmd.com/read/35316932/management-of-genitourinary-syndrome-of-menopause-in-breast-cancer-survivors-an-update
#40
REVIEW
Daniel María Lubián López
There is increasing attention about managing the adverse effects of adjuvant therapy (Chemotherapy and anti-estrogen treatment) for breast cancer survivors (BCSs). Vulvovaginal atrophy (VVA), caused by decreased levels of circulating estrogen to urogenital receptors, is commonly experienced by this patients. Women receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM), that it can in turn lead to pain, discomfort, impairment of sexual function and negatively impact on multiple domains of quality of life (QoL)...
February 24, 2022: World Journal of Clinical Oncology
keyword
keyword
5073
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.